Drug intelligence / Profile preview

aprepitant + palonosetron + dexamethasone

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A triple antiemetic combination therapy used to prevent chemotherapy-induced nausea and vomiting (CINV), particularly in patients receiving highly emetogenic chemotherapy (HEC). This combination works through multiple pathways: palonosetron blocks 5-HT3 receptors, aprepitant blocks NK-1 receptors, and dexamethasone provides additional antiemetic effects. Clinical studies have shown excellent efficacy with complete response rates of up to 100% during the acute phase (0-24 hours) and 97% during the delayed phase (24-168 hours) of CINV.

Brand names: AloxiEmend
Other names: Palonosetron and Aprepitant for CINV in ASCT

Targets

GR (Glucocorticoid receptor)HTR3A (5-hydroxytryptamine receptor 3A)TACR1 (Neurokinin‑1 Receptor)

Beyond the preview

Go deeper on aprepitant + palonosetron + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aprepitant + palonosetron + dexamethasone.

Explore the full profile